This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| iPLEDGE | |
|---|---|
| Name | iPLEDGE |
| Type | Risk Evaluation and Mitigation Strategy |
| Established | 2006 |
| Jurisdiction | United States |
| Parent organization | Food and Drug Administration |
iPLEDGE iPLEDGE is a U.S. Food and Drug Administration–mandated Risk Evaluation and Mitigation Strategy designed to prevent fetal exposure to the teratogenic drug isotretinoin. The program coordinates pharmaceutical manufacturers, prescribers, pharmacies, and patients to monitor contraception, pregnancy testing, and dispensing, and has interacted with clinical, legal, and regulatory entities since its inception.
iPLEDGE was created in response to teratogenicity concerns associated with isotretinoin and replaces earlier programs such as the S.M.A.R.T. program, aiming to reduce birth defects and ensure informed consent. Stakeholders include the Food and Drug Administration, pharmaceutical companies like Roche and Sun Pharma, professional organizations including the American Academy of Dermatology, regulatory bodies such as the Drug Enforcement Administration in policy discussion, and advocacy groups such as March of Dimes. Influential legal cases and legislation, including actions involving the U.S. Supreme Court, the United States Congress, and state medical boards like the California Medical Board, shaped program mandates and enforcement. Medical societies—American Medical Association, American Academy of Family Physicians, and American College of Obstetricians and Gynecologists—provided guidance on reproductive health, contraception counseling, and teratogenic risk communication.
The program requires registration and certification of prescribers, dispensers, and patients through a centralized registry managed by contractors under FDA oversight. Key procedural elements intersect with clinical workflows in dermatology clinics such as those affiliated with Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital, and pharmacies including CVS Pharmacy, Walgreens, and Rite Aid. Requirements mandate negative pregnancy tests at specified intervals with laboratories like Quest Diagnostics and LabCorp often used for testing, and contraceptive counseling consistent with guidelines from World Health Organization documents and guidance from the Centers for Disease Control and Prevention. Electronic health record vendors such as Epic Systems and Cerner have integrated alerts to support compliance; health insurers including UnitedHealth Group and Blue Cross Blue Shield Association have had to adapt coverage policies for testing and counseling.
Enrollment begins with prescriber certification and patient education via standardized materials approved by the Food and Drug Administration and sometimes adapted by professional groups like the American Academy of Dermatology. The registry workflow involves verification steps conducted by dispensing pharmacies and prescribers, invoking interactions with state boards such as the Texas Medical Board and international regulatory observers like the European Medicines Agency for comparative models. Compliance metrics are tracked using data systems influenced by federal programs like Medicare and Medicaid, and quality metrics reported in publications produced by academic centers such as Harvard Medical School and Stanford University School of Medicine. Enforcement actions have involved institutions including the Department of Health and Human Services and state attorneys general such as the New York Attorney General.
Studies published in journals affiliated with institutions like New England Journal of Medicine, JAMA, The Lancet, and British Medical Journal examined changes in prescribing patterns, rates of isotretinoin initiation, and pregnancy rates among users. Analyses by public health researchers at Johns Hopkins Bloomberg School of Public Health and Columbia University Mailman School of Public Health evaluated reductions in fetal exposures versus barriers to access. Clinical impacts affected specialties represented by organizations such as the American Academy of Dermatology and American College of Physicians, and intersections with reproductive health influenced practice among obstetricians in the American College of Obstetricians and Gynecologists. Pharmaceutical companies reported distribution changes to entities like McKesson Corporation and AmerisourceBergen.
Critics have cited administrative burden, privacy concerns, and unequal access raised by legal actions in federal courts and state legislatures including litigation involving litigants represented before the U.S. Court of Appeals for the Ninth Circuit and discussions in committees of the United States Congress. Patient advocacy groups such as Planned Parenthood and disability rights organizations voiced concerns about reproductive autonomy; professional societies including the American Medical Association and American Academy of Dermatology have petitioned for revisions. Privacy and data security issues implicated vendors like IBM and Microsoft in system implementations, while compliance costs affected clinics affiliated with community health centers and hospital systems including Kaiser Permanente. The FDA periodically revised requirements following stakeholder feedback and audits by the Government Accountability Office.
Comparative risk management frameworks include pregnancy prevention programs used in countries overseen by the European Medicines Agency and national agencies such as Health Canada and the Therapeutic Goods Administration of Australia. Historically, the teratogenic risks of retinoids trace back to case reports and research disseminated through institutions like University of California, San Francisco and Yale School of Medicine, and to regulatory responses following landmark studies published in journals tied to Johns Hopkins University and Massachusetts General Hospital. International pharmaceutical companies and regulatory dialogues at venues like the World Health Organization meetings influenced harmonization efforts. The program’s evolution reflects interactions among courts, legislatures, professional associations, academic centers, and patient advocates across the United States and internationally.
Category:Drug safety